Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 22.6.2020 | EN | Official Journal of the European Union | C 209/38 |

---

Action brought on 5 May 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXYMLA)

(Case T-248/20)

(2020/C 209/49)

Language in which the application was lodged: German

Parties

Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Pfizer Inc. (New York, New York, United States)

Details of the proceedings before EUIPO

Applicant for the trade mark at issue: Applicant

Trade mark at issue: Application for EU word mark RUXYMLA — Application for registration No 17 865 739

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 in Case R 1878/2019-4

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision; |

|  |  |
| --- | --- |
| — | order EUIPO to pay the costs of the proceedings, including the costs of the appeal proceedings. |

Plea in law

|  |  |
| --- | --- |
| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |

---

[Top](#document1)